Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With CHB

NCT06829329 is registered in ClinicalTrials.gov with Ausper Biopharma Co., Ltd. as lead sponsor.

NCT NCT06829329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06829329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With CHB
Lead sponsor
Ausper Biopharma Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 13, 2024
Completion date
December 31, 2026
Enrollment
105 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b